WWM
ARQT icon

Whalen Wealth Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Whalen Wealth Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,013
Closed -$233K – 177
2025
Q4 		$233K Buy
+8,013
New +$205K 0.12% 179

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Whalen Wealth Management's ARQT Position: Q1 2026 in Review

Whalen Wealth Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 8,013 shares — an estimated $233K sold.

Whalen Wealth Management first reported a position in ARQT in Q4 2025 and held it in 1 quarter. The position peaked at $233K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Whalen Wealth Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Whalen Wealth Management sold 8,013 Arcutis Biotherapeutics shares in Q1 2026, an estimated $233K.
  • Whalen Wealth Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • Whalen Wealth Management's Arcutis Biotherapeutics position peaked at $233K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Whalen Wealth Management's 13F filing for Q1 2026, filed 13 Apr 2026.